This article first appeared on GuruFocus .
-
Sales Growth:Q2 sales growth of 5%, 7.3% excluding respiratory panel sales.
-
Free Cash Flow:EUR 300 million generated in H1, a 76% increase compared to H1 2025.
-
Organic Growth:Overall H1 organic growth of 0.2%.
-
Revenue by Segment:BioFire non-respiratory grew 7% in Q2; Spotfire reagent sales grew 40% in Q2.
-
Geographical Performance:North America down 1%, Latin America up 11% organic in H1, EMEA up 2% organic, Asia Pacific down 3%.
-
Gross Profit Margin:Down 1% in H1, with a margin decrease of 70 basis points organically.
-
SG&A Costs:Down 2% in H1 due to lower variable compensation and efficiency initiatives.
-
R&D Expenses:Increased by 5% in H1, representing 13% of sales.
-
Adjusted EPS:Down 4% organically in H1.
-
Net Cash Position:EUR 236 million at the end of June.
-
2026 Outlook:Sales growth guidance of 3% to 5% organic; CVID guidance of 0% to 10% organic growth.
Release Date: July 28, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
BioMerieux SA ( BMXMF ) reported a sales growth acceleration in Q2 2026, with a 5% increase, and 7.3% growth excluding respiratory panel sales.
-
The company generated nearly EUR 300 million in free cash flow in H1 2026, marking a 76% increase compared to H1 2025.
-
BioMerieux SA ( BMXMF ) maintained a strong focus on innovation with multiple product launches, including the revised BioFire gastrointestinal panel and the SpinChip immunoassay platform.
-
The company achieved a 31% reduction in greenhouse gas emissions by the end of June 2026, aligning with its sustainability objectives.
-
BioMerieux SA ( BMXMF ) reported strong performance in industrial applications, with a 9% growth in CSOs and double-digit growth in reagents.
Negative Points
-
The company's CBITS declined by 5% organically in H1 2026, reflecting modest sales evolution in Q1.
-
BioMerieux SA ( BMXMF ) experienced a 6% decline in BioFire respiratory panels, with price erosion impacting sales.
-
The Asia Pacific region saw a 3% decline, with China down 6% and negative trends in Japan due to regulatory changes.
-
The company's gross profit margin decreased by 70 basis points on an organic basis, affected by an unfavorable product mix and increased manufacturing costs.
-
BioMerieux SA ( BMXMF ) revised its financial perspectives for 2027 and 2028, adjusting sales growth expectations to 3% to 6% annually, reflecting a slower market growth than initially anticipated.
Q & A Highlights
Q: Your new 2027-2028 targets imply a deceleration in growth. Could you explain the factors behind this, and whether competition or pricing pressures are influencing this outlook? A: The 2027-2028 sales growth foundation should be viewed in the context of Q2's performance, which showed a 5% sales growth. This is close to the midpoint of our long-term guidance, indicating a continuation rather than a deceleration. As for post-2028 growth, it's too early to predict, but our investments in innovation should support future growth.
Q: Regarding Spotfire, your new guidance suggests lower sales by 2028 compared to previous targets. What are the main drivers of this change? A: The main difference is due to exchange rate impacts. We have adjusted our guidance to reflect a percentage growth rather than a fixed euro target, making it easier to forecast.
Q: Can you provide an update on the instrument sales outlook, considering previous headwinds like geopolitical uncertainty and hospital budget pressures? A: We saw a good pickup in equipment sales in Q2, with a 5% increase, which helps clarify market trends and future outlooks. This improvement is a positive sign, although we remain cautious about ongoing market conditions.
Q: Could you elaborate on the changes in Japan's reimbursement policy and its impact on Spotfire sales? A: The Japanese authorities have restricted the use of Spotfire panels to high-risk patients, which limits its use. This is a structural change, but the definition of high-risk patients is still being finalized, which may impact sales dynamics in Japan.
Q: How do you view the competitive risk from Danaher's entry into the Hyplex market with its third-generation system? A: We see Danaher's entry as a validation of the value of Hyplex testing. While they have announced a new system, we need more details on their panels and performance to assess competitive risks fully.
Q: What is your confidence level in achieving the lower end of your 2026 guidance if the flu season is weaker than expected? A: If the Q4 2026 respiratory season matches Q4 2025, we expect to be at the lower end of our guidance. Our confidence is based on the solid performance in Q2, which provides a stable foundation for H2.
Q: Can you confirm if the tariff refunds in H1 are the full amount expected, or should we anticipate more in H2? A: The tariff refunds in H1 represent almost the full amount, with only a small portion remaining to be reimbursed in H2.
Q: How do you plan to maintain growth in the face of increasing competition and market challenges? A: We continue to focus on innovation and expanding our product offerings, such as Spotfire's non-respiratory panels, to drive growth. We are also exploring strategic M&A opportunities to strengthen our portfolio.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
